A significant concordance was found between the AR silencing gene signature and the iLINCS-derived transcriptional profiles of A375 melanoma cells treated with several AR inhibitors, as well as a number of DNA-damaging agents targeting the topoisomerase 2 (TOPO2) and TOPO1 enzymes (Fig. 4 F and Table S5). The gene discussed is AR; the disease is melanoma.